Abstract
Anesthesia and surgery have been reported to produce long-term cognitive problems, and to accelerate neurodegenerative disorders in the elderly. In previous work, we found that inhaled anesthetics enhance fibril formation and cytotoxicity of amyloid β peptide. In this work we show that the inhaled anesthetics halothane (2-bromo-2-chloro-1,1,1- trifluoroethane) and isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether) also favor intermediate oligomers of amyloid β1-40, and reduce solubility of amyloid β1-40 monomer. Size-exclusion chromatography, analytical ultracentrifugation and photo-induced cross-linking experiments indicate halothane enhancement of oligomeric species having molecular weight ∼44-100 kDa. Bis-ANS fluorescence experiments revealed that halothane stabilizes a population of diffusible oligomers relative to the monomer or the mature fibril. These data show that inhaled anesthetics lower the amyloid β1-40 concentration necessary to initiate oligomer formation, probably by preferential binding to intermediate oligomers en route to fibril formation.
Keywords: Alzheimer's disease, intermediates, protein cavities, analytical ultracentrifugation, bis-ANS fluorescence, neurodegeneration, inhaled anesthetics
Current Alzheimer Research
Title: Inhaled Anesthetic Modulation of Amyloid β 1-40 Assembly and Growth
Volume: 4 Issue: 3
Author(s): Anna Carnini, J.D. Lear and R.G. Eckenhoff
Affiliation:
Keywords: Alzheimer's disease, intermediates, protein cavities, analytical ultracentrifugation, bis-ANS fluorescence, neurodegeneration, inhaled anesthetics
Abstract: Anesthesia and surgery have been reported to produce long-term cognitive problems, and to accelerate neurodegenerative disorders in the elderly. In previous work, we found that inhaled anesthetics enhance fibril formation and cytotoxicity of amyloid β peptide. In this work we show that the inhaled anesthetics halothane (2-bromo-2-chloro-1,1,1- trifluoroethane) and isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether) also favor intermediate oligomers of amyloid β1-40, and reduce solubility of amyloid β1-40 monomer. Size-exclusion chromatography, analytical ultracentrifugation and photo-induced cross-linking experiments indicate halothane enhancement of oligomeric species having molecular weight ∼44-100 kDa. Bis-ANS fluorescence experiments revealed that halothane stabilizes a population of diffusible oligomers relative to the monomer or the mature fibril. These data show that inhaled anesthetics lower the amyloid β1-40 concentration necessary to initiate oligomer formation, probably by preferential binding to intermediate oligomers en route to fibril formation.
Export Options
About this article
Cite this article as:
Anna Carnini , J.D. Lear and R.G. Eckenhoff , Inhaled Anesthetic Modulation of Amyloid β 1-40 Assembly and Growth, Current Alzheimer Research 2007; 4 (3) . https://dx.doi.org/10.2174/156720507781077278
DOI https://dx.doi.org/10.2174/156720507781077278 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Current Gene Therapy Curcuminoids in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Iron Leads to Memory Impairment that is Associated with a Decrease in Acetylcholinesterase Pathways
Current Neurovascular Research PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Alcohol Abuse and HIV Infection: Role of DRD2
Current HIV Research Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets The Role of Phosphorylation in Synucleinopathies: Focus on Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia
Current Pharmaceutical Design Absorption, Pharmacokinetics and Disposition Properties of Solid Lipid Nanoparticles (SLNs)
Current Drug Metabolism The Role of the ATP-Binding Cassette Transporter P-Glycoprotein in the Transport of β-Amyloid Across the Blood-Brain Barrier
Current Pharmaceutical Design Commentary: Stephen William Hawking (8 January 1942 – 14 March 2018)
CNS & Neurological Disorders - Drug Targets Nanoceria: Synthesis and Biomedical Applications
Current Nanoscience On 11C Chemistry Reviews - Surveying and Filling the Gaps
Current Organic Chemistry <i>Drosophila melanogaster</i> a Versatile Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Recent Advances in Bioreactors in Tissue Engineering and Regenerative Medicine
Current Tissue Engineering (Discontinued) Role of Prolyl Endopeptidase in Intracellular Transport and Protein Secretion
CNS & Neurological Disorders - Drug Targets Adenosine-to-Inosine RNA Editing: Perspectives and Predictions
Mini-Reviews in Medicinal Chemistry